当前位置：
X-MOL 学术
›
Lancet Infect Dis
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Itraconazole and antiretroviral therapy: strategies for empirical dosing – Author's reply
The Lancet Infectious Diseases ( IF 56.3 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1473-3099(17)30582-0 Thuy Le , Antoine Adenis , Andrew Limper , Thomas Harrison
The Lancet Infectious Diseases ( IF 56.3 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1473-3099(17)30582-0 Thuy Le , Antoine Adenis , Andrew Limper , Thomas Harrison
We thank Ilan S Schwartz and Sean Wasserman for their interest in our paper on the management of HIV-associated endemic mycoses.1 Schwartz and Wasserman rightly express concern regarding the known drug–drug interaction between itraconazole and non-nucleotide reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine, which results in considerable reductions in plasma itraconazole concentrations following co-administration. NNRTIs are often included in standardised first-line antiretroviral therapy regimens in developing countries, and co-administration with itraconazole is commonly required during the consolidation and maintenance of therapy for histoplasmosis in Latin America and talaromycosis in Asia.
更新日期：2017-10-26
京公网安备 11010802027423号